Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Keros Therapeutics ( (KROS) ) has provided an announcement.
Keros Therapeutics announced updates to its corporate presentation, highlighting ongoing and future clinical trials for its product candidates, including cibotercept (KER-012) for pulmonary arterial hypertension. The company has halted dosing in certain treatment arms of the TROPOS trial due to safety concerns but continues with others, aiming to report trial data in 2025, which could impact its clinical development program and industry positioning.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for disorders linked to dysfunctional TGF-β superfamily signaling. The company is working on product candidates designed to modulate TGF-β signaling, targeting pathways critical for tissue and organ system growth, repair, and maintenance.
YTD Price Performance: -6.47%
Average Trading Volume: 909,924
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $603.2M
For an in-depth examination of KROS stock, go to TipRanks’ Stock Analysis page.
